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Abstract In order to investigate molecular characteristics
of beta-hemolytic streptococcal isolates from western Norway,
we analysed the entire emm gene sequences, obtained super-
antigen gene profiles and determined the prevalence of the
gene encoding streptococcal phospholipase A2 (SlaA) of 165
non-invasive and 34 contemporary invasive group A, C and
G streptococci (GAS, GCS and GGS). Among the 25 GAS
and 26 GCS/GGS emm subtypes identified, only emm3.1 was
significantly associated with invasive disease. M protein size
variation within GAS and GCS/GGS emm types was
frequently identified. Two non-invasive and one invasive
GGS possessed emm genes that translated to truncated M
proteins as a result of frameshift mutations. Results sugges-
tive of recombinations between emm or emm-like gene
segments were found in isolates of emm4 and stG485 types.
One non-invasive GGS possessed speC, speG, speH, speI
and smeZ, and another non-invasive GGS harboured SlaA.
speA and SlaA were over-represented among invasive GAS,
probably because they were associated with emm3. speGdys
was identified in 83% of invasive and 63% of non-invasive
GCS/GGS and correlated with certain emm subtypes. Our
results indicate the invasive potential of isolates belonging to
emm3, and show substantial emm gene diversity and possible
lateral gene transfers in our streptococcal population.
Introduction
Group A streptococci (Streptococcus pyogenes, GAS) cause
human disease ranging from mild skin and throat infections
to necrotising fasciitis (NF) and streptococcal toxic shock
syndrome (STSS). Group C streptococci (GCS) and group
G streptococci (GGS) causing human infections are most
often of the species Streptococcus dysgalactiae subsp.
equisimilis (SDSE) and are phylogenetically related to S.
pyogenes. SDSE has recently emerged as bacteria increas-
ingly associated with invasive human infections resembling
those caused by GAS [1, 2, 3]. GAS produces a variety of
cell-wall-anchored virulence proteins. Among them is the
antiphagocytic M-protein, an alpha-helical coiled-coil dimer
anchored in the cell wall and extending from the cell surface.
The basic central structure consists of conserved, variable and
hypervariable repeat blocks with a seven residue periodicity
(labelled C, B and A blocks respectively), and the N-terminal
portion terminates in a non-helical hypervariable opsonogenic
segment [4]. M proteins of GAS can be divided into class I
and class II molecules based on variations in the structure of
repeated segments in the conserved C-terminal region [5]. M
proteins have also been identified in GCS and GGS
associated with human disease and have been shown to
have antiphagocytic activity and be structurally similar in
their conserved domain to class I molecules of GAS [6, 7].
The emm gene encodes the M protein, and emm typing based
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on the nucleotide sequence encoding the 50N-terminal
amino acids (aa) of the mature protein is a major
epidemiological tool in surveys on GAS, GCS and GGS.
The M protein is multifunctional, and the variable and
conserved domains also seem to play a significant role in the
pathogenesis of streptococcal disease [8, 9, 10]. Diversity
across the full length of emm genes, including variations in
the number of repeats in the hypervariable, variable or
conserved regions of emm genes have previously been
shown among GAS within types emm6, emm18 and
emm28 [11, 12, 13, 14]. Furthermore, in a recent phylogenetic
analysis based on the whole surface exposed M protein a high
degree of M protein diversity was observed within B- and C-
repeats of Belgian GAS isolates [15]. Full-length emm gene
analysis is also interesting from a vaccine perspective, as both
N-terminal opsonogenic fragments and epitopes from C-
repeats of GAS M proteins have formed the basis of different
GAS vaccine candidates [16, 17].
Phage genomes are mobile genetic elements, and phages
integrated into the bacterial chromosome have accounted
for up to 10% of the total genome in GAS [18]. Genes
encoding the majority of the virulence-associated exopro-
teins called streptococcal superantigens (SAgs) are carried
on phages, and the gene encoding streptococcal extracellu-
lar phospholipase A2 (SlaA) was localised on the same
phage as the SAg speK in the M3 strain MGAS315 [19].
Phages are probably the primary means of lateral gene
transfer among GAS, GCS and GGS, and genetic recombi-
nations between related streptococcal species are likely to
change the pathogenic potential of the recipient strains. The
phage-mediated SAgs speA, speC, ssa and speM, the
chromosomally encoded smeZ and the speG orthologue
speGdys have previously been identified in GCS/GGS
isolates [20, 21, 22], but SlaA has not previously been
documented in SDSE. Studies on GAS, GCS and GGS
epidemiology often include isolates associated with inva-
sive disease only, and over-representation of certain emm
types/M serotypes or streptococcal clones could merely
reflect the distribution of these in the geographical area
under investigation. However, results from studies compar-
ing strains causing mild and serious infections have not
been unequivocal in this respect. Although certain strepto-
coccal emm types or clones correlate significantly with
invasive disease [23, 24], other studies do not identify
strains or emm types significantly associated with severe
disease manifestations [25].
Invasive group A streptococcal (iGAS) disease is
endemic in our community, and outbreaks of invasive
streptococcal disease with different emm/M types have
occurred during the last two decades [26, 27]. In order to
compare molecular characteristics of isolates associated
with mild and severe disease and search for evidence of
horizontal gene transfers between related streptococcal
strains, we have analysed the full-length emm genes, SAg
gene profiles and the prevalence of SlaA in a sample of
non-invasive and contemporary invasive GAS, GCS and
GGS isolates from the same geographical distribution in
western Norway during 2005–2006.
Materials and methods
Study population and bacterial isolates
We included GAS, GCS and GGS isolates associated with
non-invasive and invasive infections in western Norway
during a 13-month period from February 2005 to March
2006. The non-invasive isolates (n=165) were the same as in
a previous study [28]. The isolates associated with invasive
streptococcal disease (n=34) included all the available
contemporary invasive isolates (one per patient) identified
in the laboratory of bacteriology, Haukeland University
Hospital. Invasive disease was defined by isolation of
GAS, GCS or GGS from a normally sterile site, or from a
non-sterile site in combination with streptococcal toxic shock
syndrome (STSS) or necrotising fasciitis (NF). STSS was
defined using criteria originally meant for GAS [29], and NF
was defined as described previously [30]. The study was
approved by the Privacy Appeals Board and the Regional
Committee of Medical Research Ethics.
Out of the 22 isolates associated with iGAS disease, 14
were from blood, 5 were from other sterile sites (synovial
fluid, peritoneal fluid or bone) and 3 were obtained from
skin or soft tissue in association with NF. We identified 1
GCS and 11 GGS isolates associated with invasive disease;
10 were from blood, 1 GGS isolate was from a soft tissue
biopsy in association with NF and the GCS strain was
obtained from synovial fluid. All 199 isolates were beta-
haemolytic and formed large colonies on blood agar. Group
carbohydrate was ascertained using the Streptococcal
Grouping kit (Oxoid, Cambridge, UK).
emm typing and sequence analysis
emm typing of the invasive isolates was done as described
for the isolates associated with non-invasive infection [28],
with previously reported primers [31]. In order to analyse
the entire emm genes of the 199 isolates, the primers used
for emm amplification were also used for sequencing in
both directions. The emm genes predicted to encode
truncated M proteins were sequenced twice. The nucleotide
and predicted protein sequences downstream of the signal
peptide cleavage site were analysed. Alignments of all
sequences belonging to the same emm type were obtained
using the ClustalW2 software program (http://www.ebi.ac.
uk/Tools/clustalw2/index.html) or EMBOSS Pairwise
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Alignment Algorithms (http://www.ebi.ac.uk/Tools/emboss/
align/) when appropriate. The sequences of different alleles
of the same emm type were also aligned and analysed
manually. Sequence homology to the full length of the
sequences was sought using BLASTN (GenBank).
Detection of SAg genes, SlaA and the 16S ribosomal RNA gene
A multiplex PCR with primer pairs for the 11 GAS exotoxin
genes speA, speC, speG, speH, speI, speJ, speK, speL, speM,
ssa and smeZ was used as described [32]. In order to cover
the allelic variations of smeZ, we also used a simplex PCR
with an alternative primer pair [23]. Simplex PCR amplifi-
cations of speGdys and SlaA were performed with primers
previously described [33]. The speGdys primers amplified
gene segments of equal size in both speGdys and speG, while
the speG primers included in the multiplex PCR only
amplified alleles of speG. Thus, all 199 isolates were
screened for the presence of the 11 GAS exotoxin genes
and SlaA, while only GCS/GGS isolates were subjected to
PCR with the speGdys primers. The single non-invasive GGS
of type stG6.7 possessed genes encoding speC, speG, speH,
speI and smeZ, and 1 of the 3 non-invasive GGS of type
stG10.0 possessed SlaA. The SAg genes and SlaA amplified
from GGS were sequenced twice in both directions using the
same primers as for initial amplification. In order to confirm
that these two GGS isolates were of the species SDSE we
sequenced their 16S ribosomal RNA genes using a previously
reported primer pair [34].
Nucleotide sequence accession numbers
Sequence data were assigned to GenBank accession numbers:
FJ531815-FJ5319 (emm4.5, emm4.0–4, emm4.0–1, emm4.0–
2, emm4.0–3), FJ531820 (emm12.0-2), FJ531821
(emm12.17), FJ531822 (emm22.3), FJ531823 (emm22.0),
FJ531824 (emm28.4), FJ531825 (emm28.0-2), FJ531826
(emm49.3), FJ531827 (emm73.0), FJ531828 (emm75.0),
FJ531829 (emm78.3), FJ531830 (emm80.0), FJ531831
(emm80.1), FJ531832 (emm82.0), FJ531833 (emm87.0–1),
FJ531834 (emm87.0–2), FJ531835 (emm89.0–1), FJ531836
(emm89.0–3), FJ531837 (stC1400.5), FJ531838 (stC1400.0),
FJ531839 (stC74a.0–2), FJ531840 (stC6979.0), FJ531841
(stCK401.3), FJ531842 (stG166b.0–1), FJ531843
(stG166b.0–2), FJ531844 (stG245.0), FJ531845 (stG245.1),
FJ531846 (stG480.0), FJ531847 (stG4222.0), FJ531848
(stG485.0–1), FJ531849 (stG485.0–2), FJ531850
(stG4831.0), FJ531851–FJ531857 (stG6.0-1, stG6.0–3,
stG6.0–4, stG6.0–2, stG6.3, stG6.4, stG6.5), FJ531858–
FJ531862 (stG643.0–1, stG643.0–2, stG643.1–1, stG643.1–
3, stG643.1–2), FJ531863–FJ531868 (stG652.0–1,
stG652.0–4, stG652.0–2, stG652.0–3, stG652.1, stG652.3),
FJ493181 (emm1.0–2), GQ845001 (stC74a.0–1), GQ923927
(stG6.7), GU015026 (stG6792.0), GU015027 (emm11.7),
GQ923928–GQ923932 (SDSE smeZ, speC, speG, speH,
speI), GQ923933 (stG10.0), GQ923934 (SDSE SlaA). The
alleles emm1.0–1, emm2.0, emm3.1, emm9.0, emm12.0–1,
emm28.0–1, emm77.0–1, emm77.0–2, emm82.1, emm89.0–
2, emm92.0 and stG62647.0 exactly matched emm gene
sequences with the following GenBank numbers respectively:
CP000017, CP000260, AE014074, EF460485, CP000259,
CP000056, DQ010927, AY139399, DQ010928, EU089975,
EF460478 and DQ522163.
Statistical analysis
Nominal data were analysed using Stata Statistical Software;
version 10 (Stata). Fisher’s exact test was used in order to
assess the association between disease type (invasive or non-
invasive) and emm type, SAg genes and SlaA. Because
multiple comparisons were performed, both unadjusted and
Bonferroni corrected p values were calculated. A two-sided
p value <= 0.05 was considered significant.
Results
emm types and clinical manifestations
Table 1 shows the distribution of emm types and clinical
manifestations associated with GAS, GCS and GGS disease.
Seven GAS and seven GCS/GGS emm types were shared by
both non-invasive and invasive isolates. Among these 14
types, emm3 was the only one significantly associated with
invasive disease (unadjusted p<0.001, Bonferroni corrected
p<0.016). All emm3 isolates belonged to subtype emm3.1
and accounted for 32% of the invasive and 4% of the non-
invasive isolates. The emm sequence of the entire sequenced
region was identical in these isolates. emm3, 12 and 28
accounted for 68% of the total iGAS isolates. Among the
GCS/GGS isolates, the predominant types were stG485,
stG6 and stG643, accounting for 59% of the invasive and
58.5% of the non-invasive isolates. Skin or soft tissue
infections were the most frequent primary site of both the
total non-invasive (74.5%) and invasive (41%) infections.
NF was associated with both GAS (n=3, emm types emm1.0,
emm3.1 or emm28.0) and GGS (n=1, emm type stC74a.0).
STSS developed in 2 patients with NF (emm1.0 or emm3.1)
and in 2 patients with primary bacteraemia or skin/soft tissue
infection (stG480.0 or stG485.0).
Variations in the entire emm sequences and predicted M
proteins
M protein size variations were inferred within 8 out of 13
GAS emm types and 7 out of 11 GCS/GGS emm types
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identified in two or more strains (Fig. 1). Deletions/
insertions of repeated segments occurred mainly in the
conserved regions of emm genes in GAS, while such
variations were seen in the hypervariable, variable or
conserved regions of emm genes in GCS/GGS. Nucleotide
polymorphisms resulting in aa variations occurred within 5
GAS emm types and 7 GCS/GGS emm types. Novel
subtypes, stG6.5 and stG6.7, were found in 2 GGS isolates,
both predicted to encode truncated M proteins of only 56
and 42 residues respectively. The former was associated
with severe soft tissue infection together with bacteraemia
and the latter with mild skin infection. Both had unique
single nucleotide deletions in the repeated segments of the
hypervariable region (HVR) compared with other alleles of
stG6, causing frameshift and stop codons downstream. A
single nucleotide insertion in the emm gene of another non-
invasive isolate of type stG652.0 caused a frameshift, and
this emm gene was predicted to generate a truncated M
protein of 110 aa. Eight alleles (emm1.0–2, emm78.3,
emm82.1, emm89.0–1, stC1400.0, stG6.5, stG652.0–3 and
stG6792.0) were exclusively found among isolates associ-
ated with invasive disease. Four out of 9 non-invasive
isolates possessed an emm4 allele (emm4.0–4), which was
highly divergent from the other alleles of this subtype in the
conserved region, probably as a result of intergenic
recombination between emm4 and the emm-like gene enn4
(Fig. 2a). Among the 13 isolates possessing stG485.0, we
identified 2 alleles (stG485.0–1 and –2), which were highly
Table 1 emm types and clinical manifestations among group A, group C and group G streptococci (GAS, GCS and GGS)
emm type Number of
non-invasive
isolates
Number of
invasive isolates
Group
carbohydrate
Clinical manifestations of invasive disease
A C G Primary
bacteraemia
Skin or soft
tissue infectiond
NF STSS Othere
emm1 4 2 6 1 1 1
emm3 a 4 7 11 1 1 1 1 4
emm12 19 3 22 3
emm28 22 5 27 1 1 3
emm78 0 1 1 1
emm82 6 1 7 1
emm87 13 1 14 1
emm89 6 2 8 2
other GAS emm typesb 27 0 27
stC1400 1 1 1 1 1
stC74a 4 1 5 1
stG480 3 1 4 1 1
stG485 10 3 3 10 2 1 1
stG6 14 2 2 14 1 1
stG643 14 2 4 12 2
stG652 5 1 2 4 1
stG6792 0 1 1 1
other GCS/GGS emm typesc 13 0 1 12
Total 165 34 123 13 63 7 14 4 4 9
a Significantly associated with invasive disease, unadjusted p<0.001, Bonferroni corrected p<0.016
b emm2.0 (n=2), emm4.0 (n=8), emm4.5 (n=1), emm9.0 (n=3), emm11.7 (n=1), emm22.0 (n=1), emm22.3 (n=3), emm49.3 (n=1), emm73.0 (n=1),
emm75.0 (n=1), emm77.0 (n=2), emm80.0 (n=1), emm80.1 (n=1), emm92.0 (n=1)
c stC6979.0 (n=1), stCK401.3 (n=1), stG10.0 (n=3), stG166b.0 (n=2), stG245.0 (n=1), stG245.1 (n=1), stG4831.0 (n=1), stG4222.0 (n=2), stG62647.0
(n=1)
d Erysipelas or cellulitis associated with bacteraemia (n=11), suppurative tenosynovitis (n=2), pyomyositis (n=1)
e Arthritis (n=3), puerperal septicaemia (n=2), meningitis (n=1), endocarditis (n=1), peritonitis (n=1), mastoiditis (n=1)
Fig. 1 Segments of a group A streptococci (GAS) and b group C/
group G streptococci (GCS/GGS) M protein sequences differing in
size mainly because of variation in the number of repeats in the
hypervariable, variable and/or conserved regions. emm alleles encoding
the M proteins are italicised in the left margin and alleles shown in bold
type are exclusively associated with invasive isolates. Numerals
representing the first amino acids of each line are placed to the left of
the sequences. Dashes indicate deletions and dots indicate stop codons.
To highlight our findings, repeated segments of varying sizes in the
hypervariable/variable regions (pink or brown) and C-repeat sub-blocks
of 28 (blue) or 7 (red, green) amino acids are shown

426 Eur J Clin Microbiol Infect Dis (2011) 30:423–433
a 
emm1.0-1   197 QISDASRQSLRRDLDASREAKKQVEKDLANLTAELDKVKEDKQISDASRQGLRRDLDASREAKKQVEKDLANLTAELDKVKEEK
emm1.0-2   197 QISDASRQSLRRDLDASREAKKQVEKDLANLTAELDKVKEDK------------------------------------------  
emm4.5     124 QISDASRQGLSRDLEASRAAKKELEAKHQKLETEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALTAEHQKLKEEK
emm4.0-1   124 QISDASRQGLSRDLEASRAAKKELEAEH-------QKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALTAEHQKLKEDK
emm4.0-2   124 QISDASRQGLSRDLEASRAAKKELEAEH-------QKLKEEKQISDASRQGLSRDLEASRAAKKELEAEH-------QKLKEEK
emm4.0-3   124 ------------------------------------------QISDASRQGLSRDLEASREAKKKVEADLAALTAEHQKLKEDK
emm22.0   1   ESSNNAESSNISQESKLINT---LTDENEKLREELQQYYALSDAKEEEPRYKALRGENQDLREKERKYQD 
emm22.3   1   ESSNNAESSNISQESKLINTINTLTDENEKLREELQQYYALSDAKEEEPRYKALRGENQDLREKERKYQD 
emm28.0-1  138 QISEASRKSLSRDLEASRAAKKDLEAEHQKLKEEKQISDASRQGLSRDLEASRAAKKDLEAEH
emm28.0-2  138 QISEASRKSLSRDLEASRAAKKDLEAEH-----------------------------------  
emm77.0-1  102 QISEASRKSLSRDLEASRAAKKELEAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALNAEHQKLKEEKQISDASRQGLSRDLEASREAKKK
emm77.0-2  102 QISEASRKSLSRDLEASRAAKKELEAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADL-------------------------------------  
emm77.0-1 202 VEADL
emm77.0-1  165 -----  
emm80.0    142 QISDASRQGLRRDLDASREAKKQVEKDLANLTAELGKVKEEKQISDASRQGLRRDLDASREAKKQVEKDL
emm80.1   142 QISDASRQGLRRDLDASREAKKQVEKDL------------------------------------------  
emm87.0-1  137 QISEASRKSLSRDLEASREAKKKVEADLAALNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALNAEHQKLKEEKQISDASRQGLSRDLEA
emm87.0-2  137 QISEASRKSLSRDLEASREAKKKVEADLAALNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADL------------------------------  
emm87.0-1  237 SREAKKKVEADL
emm87.0-2  207 ------------  
emm89.0-1  105 QISEASRKSLSRDLEASREAKKKVEADLAALTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALTAEHQKLKEEKQISDASRQGLSRDLEA
emm89.0-2  105 QISEASRKSLSRDLEASRAAKKDLEAEH-------QKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAALTAEHQKLKEEKQISDASRQGLSRDLEA
emm89.0-3  105 QISEASRKSLSRDLEASRAAKKDLEAEH-------QKLKEEKQISDASRQGLSRDLEASREAKKKVEADL-----------------------------  
emm89.0-1  205 SREAKKKVEADL
emm89.0-2  198 SREAKKKVEADL
emm89.0-3  168 ------------  
b
stC1400.0   92  DISDLQKKLQDLKDDKSLAEAGYANSYKHHQEQLAEKDKDISDLQKKLQDLKDDKSLAEAGYANSYKHHQEQLAEKDK
stC1400.5   92  DISDLQKKLQDLKDDKSLAEAGYANSYKHHQEQLAEKDK---------------------------------------  
stC74a.0-1  215 QISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEQNKISEASRKGLRRDLDASREAKKQVEKDLAN
stC74a.0-2  215 QISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEQNKISEASRKGLRRDLDASREAKKQVEKAL--  
stC74a.0-1  315 LTAELDKVKEEKQISDASRKGLRRDLDASREAKKQVEKAL
stC74a.0-2  313 ----------------------------------------  
stG166b.0-1 159 QISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEQNKISEASRKGLRRDLNASREAKKQLEAEHQK
stG166b.0-2 159 QISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEQN------------------------------  
stG166b.0-1 259 LEEQN
stG166b.0-2 229 -----  
stG245.0    49  AEYNSLLDEHNSLVKKMRVMNDSLQATERNYESLVNKMEVVNDSLQNTKREYDLIEEELGKKLKENQDLEEKLKDKEFYLGETLRYINELDLKLGQLNID  
stG245.1    49  AEYNSLLDEHNSLVKKMRVMNDSLQ---------------------NTKREYDLIEEELGKKLKENQDLEEKLKDKEFYLGETLRYINELDLKLGQLNID  
stG245.0    149 NIDLKHELEQEKQKAEADRQTLEAEKAKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLE
stG245.1    128 NIDLKHELEQEKQKAEADRQTLEAEKAKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLEEEKQISDASRQSLRRDLDASREAKKQLEAEYQKLE
stG245.0    249 EQNKISEASRKGLRRDLDASREAKKQLEAEHQKLEEQN
stG245.1    228 EQN------------------------------------  
stG6.0-1    33  --------------NQELTKKNEELTKKLDEAEKELGKSDQSLSENASKIQKLEAEKAQVEEKLKEARLNYQDLAEVQTHIREKLKAEKAQVEEKLKEAR
stG6.0-2    33  --------------NQELTKKNEELTKKLDEAEKELGKSDQSLSENASKIQKLEAEKAQVEEKLKEARLNYQDLAEVQTHIREKLKAEKAQVEEKLKEAR
stG6.3      33  --------------NEELTKKNEELTKKLDEAEKELGK---------------------VEEKLKEARLNYQDLAEVQTHIREKLKAEKAQVEEKLKEAR
stG6.4      33  ---------------------NEELTKKLDEAEKELGK---------------------VEEKLKEARLNYQDLAEVQTHIREKLKAEKAQVEEKLKEAR
stG6.5     33  NEELTKKNEELTKKNEELTKKMRS. 
stG6.7      33  --------------NQELTKKMRS.                  
stG6.0-1    119 LNYQDLAEVQTHIREKLEAEKAALETRKAELEKALEGAMNFSTEDSAKIKALEEEKAALEAKKAALETEKADLEHQSQVLNANRQSLRRDLDASREAKKQ
stG6.0-2    119 LNYQDLAEVQTHIREKLEAEKAALETRKAELEKALEGAMNFSTEDSAKIKALEEEKAALEAKKAALETEKADLEHQSQVLNANRQSLRRDLDASREAKKQ
stG6.3      98  LNYQDLAEVQTHIREKLEAEKAALETRKAELEKALEGAMNFSTEDSAKIKALEEEKAALEAKKAALETEKADLEHQSQVLNANRQSLRRDLDASREAKKQ
stG6.4      91  LNYQDLAEVQTHIREKLEAEKAALETRKAELEKALEGAMNFSTEDSAKIKALEEEKAALEAKKAALETEKADLEHQSQVLNANRQSLRRDLDASREAKKQ
stG6.0-1    219 LEAEYQKLEEQNKISEASRKGLRRDLDASREAKKQLEAEHQKLEEQN
stG6.0-2    219 LEAEHQKLEEQN-----------------------------------  
stG6.3      198 LEAEHQKLEEQNKISEASRKGLRRDLDASREAKKQLEAEHQKLEEQN
stG6.4      191 LEAEHQKLEEQN-----------------------------------            
stG643.0-1   47  EGDLEFLSQELDKTVSKHIESSDKYKKEIGELKSSLDQMASTLSESSRKVGEVSNENKALKEEAAKKEEELKGLQEAFDQTVSKHIESGDKYKKEIGELK
stG643.0-2   47  EGDLEFLSQELDKTVSKHIESSDKYKKEIGELKSSLDQMASTLSESSRKVGEVSNENKALKEEAAKK---------------------------------  
stG643.1-2  47  EGDLEFLSQELGKTVSKHIESSDKYKKEIGELKSSLDQMASTLNESSRKVGEVSNENKALKEEAAKKEEELKGLQEAFDQTVSKNIESGDKYKKEIGELK 
stG643.0-1   147 SSLDQMASTLSESSRKVGEVSNENKALKEEAAKKDQANKISEASRKGLRRDLDASREAKKQLEAEHQKLEEQNKISEASRKGLRRDLDASRAAKKQVEKD
stG643.0-2   114 ----------------------------------DQANKISEASRKGLRRDLDASREAKKQLEAEHQKLEEQNKISEASRKGLRRDLDASRAAKKQVEKD
stG643.1-2  147 SSLDQMASTLSESSRKVGEVSNENKALKEEAAKKDQAN-----------------------------------KISEASRKGLRRDLDASREAKKQVEKD
stG643.0-1   247 LANLTAELDKVKEEK
stG643.0-2   180 LANLTAELDKVKEEK
stG643.1-2  212 LANLTAELDKVKEEK
stG652.0-1   38  AYKAQEEAYKAQEEAYKAQEETLLRVLRENSDLFKKKQKELNELKEAYKAQEETLQGVLRDRSDLFKEKQKELNELKEAYKAQEETLQGVLRDRSDLFKE 
stG652.0-3   38  AYKAQEEAYKAQEE--------------------------------------------------------------------------------------  
stG652.0-4   38  AYKAQEEAYKAQEE-------TLLRVLRENSDLFKKKQKELNELKEAYKAQEE-----------------------------------------------  
stG652.1    38  AYKAQEE---------------------------------------------------------------------------------------------  
stG652.0-1   138 KQKELNELKEAYKAQEETLQGVLRDRSKLFEEKQRELTDLKEAIK  
stG652.0-3   52  -----------------TLQRVLRDRSKLFEEKQRELTDLKEAIK  
stG652.0-4   84  -----------------TLQGVLRDRSKLFEEKQRELTDLRRSD.  
stG652.1   45  -----------------TLQGVLRDRSKLFEEKQRELTDLKEAIK
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divergent downstream of nucleotide 333, indicating lateral
genetic transfer between different emm genes (Fig. 2b). All
3 invasive and 6 out of 10 non-invasive isolates belonging
to stG485.0 possessed allele stG485.0–2.
C-repeat analysis among GAS, GCS and GGS
Thirty-four GAS isolates (28%) had 4 C-repeats, 38 isolates
(31%) had 3 C-repeats and the remaining 51 GAS isolates
(41%) had 2 C-repeats. We identified 4 C-repeats in 34
GCS/GGS isolates (47%), 30 isolates had 3 C-repeats
(41%), eight isolates had 5 C-repeats (11%) and only one
isolate contained 2 C-repeats. We also checked the C-repeat
regions for the presence of J14, a short peptide sequence
that forms the basis for GAS vaccine candidates based on
conserved M protein epitopes [35]. J14 was identified
among all isolates of GAS class 1 M proteins (emm1,
emm3, emm12 and emm80). The remaining GAS isolates
possessed class II M proteins. All these isolates harboured
the J14 homologue J14.1, except for four isolates possess-
ing the recombinant emm4.0–4 allele and a single isolate
harbouring emm78.3. The predicted M protein of the latter
contained a J14 homologue sharing 13 out of 14 aa with
J14.1. Seventy-two out of 73 predicted GCS/GGS M
proteins available for C-repeat analysis (i.e. all except the
three truncated M proteins) contained J14; the isolate
possessing stC6979.0 contained a J14 homologue sharing
13 out of 14 aa with J14. J14.1 was not detected in any of
the GCS/GGS M proteins.
SAg gene profiles and prevalence of SlaA, related to GAS
emm types
Table 2 shows the distribution of SAg genes and SlaA
within emm types. Each GAS emm type had a fairly similar
SAg gene profile regardless of the source of the isolates.
However, it is noteworthy that speC was present in all
invasive isolates of five different emm types, but was
detected in only some of the non-invasive isolates within 4
of these 5 types. ssa seemed to be more frequently detected
among invasive than non-invasive GAS isolates possessing
emm12, but there were only 3 invasive isolates. speA,
detected in all isolates possessing emm3 or emm1 and in 1
non-invasive isolate harbouring emm28, and was signifi-
cantly over-represented among invasive strains
(unadjusted p=0.002, Bonferroni corrected p=0.032). speH
and speI, previously reported to be on the same phage [36],
were found in all isolates of types emm12, emm82, emm49
and emm73. speG was found in all GAS isolates except in
all 8 isolates of emm4.0 and the 2 isolates that belonged to
emm77.0, while only isolates of emm2.0 (n=2) and
emm49.3 (n=1) failed to amplify smeZ. Thus, these isolates
either lacked the same speG or smeZ or had allelic
variations not detected by our primers. SlaA and speK,
identified previously on the same phage [19], were detected
in all 11 isolates harbouring emm3, in 1 out of 5 invasive
and in 13 out of 22 non-invasive emm28 isolates, and in 2
isolates of either emm80.0 or emm77.0. However, the single
isolate of emm80.1 seemed to harbour only speK, as SlaA
was negative.
Identification of SAg genes and SlaA in GCS/GGS
speGdys was identified in 10 out of 12 (83%) invasive and
40 out of 64 (63%) non-invasive isolates (unadjusted p=
0.202). As shown in Table 3, the presence of this SAg gene
correlated with certain emm types, and within types
stC1400, stG6, stG643 and stG652 also with specific
subtypes. The GGS isolate of emm type stG6.7 possessed
speC, speG, speH, speI and smeZ. One out of three non-
invasive GGS isolates of emm type stG10.0 harboured
SlaA. The sequenced regions of the speC-H-I and SlaA
genes were identical to corresponding genes previously
identified in GAS and deposited in GenBank. The speH,
speI and SlaA alleles found in GGS were also highly
homologous to alleles of these genes identified in Strepto-
coccus equi subsp. equi isolated from horse (Streptococcus
equi subsp. equi 4047, complete genome, GenBank
accession number FM204883). The sequenced region of
the GGS smeZ and speG alleles identified, differs from their
closest match in GAS only by a single nucleotide substitution
(smeZ-3, GenBank accession number AB046865 and speG,
GenBank accession numbers AM295007, CP000261,
a 
emm 4.0-4 
b 
stG485.0-1 
stG485.0-2
1 100 % 463 464    100 %             828         
emm4.0 enn4
1 100 % 613 614 954 955 132693-94 %99.7-100%
    stC839 
stC74a.0 
stG166b.0  
    stG485.0                stG245.0 many emm types    
1 100%       374       375 97.1 %           1317
      stG485.0  stG4222.1
Fig. 2 Analysis of the full length emm gene sequences of a allele
emm4.0–4 and b alleles stG485.0–1 and stg485.0–2. Genes or gene
segments deposited in GenBank with close homology to the analysed
genes are shown above the lines. The percentage of homology
between these gene segments and segments of the genes analysed
(indicated by base numbers) is shown below the lines. The GenBank
accession numbers of the sequences referred to in the figure are
DQ010939 (emm4.0), Z11602 (enn4), AF239717 (stG485.0),
DQ522169 (stC74a.0), FJ531842 (stG166b.0), FJ531844 (stG245.0),
DQ522164 (stC839) and DQ010924 (stG4222.1). The relatively low
homology between the C-terminal segment of stG485.0–1 and other
emm types was mainly due to a 21 bp deletion in stG485.0–1
compared with the corresponding segments of emm genes deposited in
GenBank
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CP000259 and CP000056). Sequencing of the 16S rRNA
gene confirmed the identity of these two GGS isolates as
SDSE.
Discussion
To our knowledge, this is the first study comparing the full-
length emm genes, the distribution of all known strepto-
coccal SAg genes and the prevalence of SlaA among
invasive and contemporary non-invasive GAS, GCS and
GGS isolates. Although the relatively small sample size,
short study period and lack of geographical diversity do not
allow firm conclusions, emm3 seemed to be particularly
associated with highly virulent GAS isolates. The preva-
lence of isolates belonging to other major GAS emm types,
like emm12 and emm28, indicated a widespread occurrence
of these in the community and not a distinct ability to cause
severe disease. emm1, over-represented among isolates
associated with iGAS disease in Norway during 1988–
2003 and in other western countries [13, 37, 38, 39], wasTa
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Table 3 SAg genes among GCS and GGS
emm subtype Number of
non-invasive
isolates
Number of
invasive
isolates
SAg gene(s)
detected
stC1400.0 0 1 speG dys
stC1400.5 1 0
stC6979.0 1 0 speG dys
stC74a.0 4 1 speG dys
stCK401.3 1 0 speG dys
stG166b.0 1 0 speG dys
stG166b.0 1 0
stG10.0 3 0 speG dys
stG245.0/.1 2 0
stG480.0 3 1 speG dys
stG485.0 10 3 speG dys
stG4831.0 1 0
stG4222.0 2 0
stG6.0 9 0 speG dys
stG6.1/.3/.4/.5 4 2
stG6.7a 1 0 speC, speG, speH,
speI, smeZ
stG643.0 11 0
stG643.1 3 2 speG dys
stG652.0/.1 4 1 speG dys
stG652.3 1 0
stG6792.0 0 1 speG dys
stG62647.0 1 0 speG dys
Total 64 12
a Erroneously classified as stG6.1 in a previous study [28]
Eur J Clin Microbiol Infect Dis (2011) 30:423–433 429
infrequently identified among our GAS isolates. These four
types accounted for 46% of the invasive GAS isolates in a
recent Strep-EURO report [40], and isolates possessing
emm1 or emm3 have previously been associated with severe
disease manifestations like STSS and NF [37, 41, 42]. In
western Norway, emm1, emm3 and emm6 accounted for
86% of the isolates associated with iGAS disease during
1992–1994 [13], while emm89, emm1 and stG10 were the
dominating types during an outbreak of severe streptococ-
cal disease in 2002–2003 [27]. The three most prevalent
GCS/GGS emm types among both non-invasive and
invasive isolates in our material (stG485, stG6 and
stG643) were recently reported to be frequently associated
with severe GCS/GGS disease in the United States [43],
and stG485 and stG6 were prevalent types among invasive
GGS isolates collected in Israel, Taiwan and Japan during
the last two decades [1, 2, 33]. stG10, a type that
significantly correlated with invasive GCS/GGS disease in
Portugal during 1998–2004 [24], was absent from our
invasive sample. The relatively low prevalence of emm1
and the absence of emm6 and stG10 among our invasive
isolates illustrate that predominant emm types associated
with severe streptococcal disease vary with time and
geographical location.
The HVRs of GAS M proteins elicit the production of
protective antibodies in the host, and mutations in this
region of emm genes could promote escape from immune
clearance [44]. It is conceivable that GCS and GGS M
proteins also contain opsonic epitopes and that antigenic
variation in their HVRs could be the means of evasion from
host antibody recognition. The emm type diversity in our
region was illustrated by the identification of 25 GAS and
26 GCS/GGS emm subtypes. One of the three isolates with
a predicted truncated M protein was from severe soft tissue
infection together with bacteraemia, indicating the involve-
ment of virulence factors other than the M protein. The
frequently observed in-frame emm gene size mutations
within emm types of both GAS and GCS/GGS were
probably caused by homologous intragenic recombinations
[12] or slipped-strand mispairing, and generated variable
numbers of A-, B- and C-repeats. Such size mutations
involving B- and C-repeats in emm6 and C-repeats in
emm18 and emm28 have previously been reported [11, 13,
14]. It is not shown that B-repeats contain opsonogenic
epitopes, but studies on the M5 protein have indicated that
these segments are crucial for phagocytosis resistance [10].
The binding sites for the complement regulatory protein
CD46 are located within the C-repeat of GAS M protein,
and the bound CD46 mediate adherence to keratinocytes
and invasion of human lung epithelial cells [8, 9]. Thus,
changes in the hypervariable, variable and conserved
segments of M proteins may influence many aspects of
streptococcal virulence.
Interestingly, the vast majority of GAS and GCS/GCS
isolates in the present study harboured either J14 or J14.1.
J14 evoked opsonising antibodies against GAS isolates of
many emm types, including those that harbour J14.1, in a
previous study [35]. J8, a peptide fragment contained
within J14, has been proposed as a GAS vaccine candidate.
J8 conjugated to diphtheria toxin (DT) induced the
production of opsonic antibodies against GAS in a mouse
model [16], and both J8-DT- and J14-DT-immunised mice
were shown to be protected from challenge with GAS strains
expressing J14 or J14.1 (Michael Batzloff, Queensland
Institute of Medical Research, unpublished data). In a recent
study, GAS and GCS/GGS isolates from Fiji were emm and
C-repeat typed. As among our streptococcal isolates, nearly
all of those isolates contained either J14 or J14.1 [45]. The
26-valent GAS M protein vaccine composed of epitopes
from the hypervariable end [17] would theoretically cover
86% of our invasive and 65% of our non-invasive GAS, but
only 26% of the GAS isolates from Fiji. The J8 vaccine
candidate would protect against a broader range of emm
types, and theoretically could also induce cross-protective
immunity against GCS/GGS. Therefore, a vaccine based on
conserved M protein epitopes may be an alternative to a
multivalent M protein vaccine in areas with a high burden of
GAS, GCS and GGS disease.
Genetic recombinations between GAS, GCS and GGS
involving SAg genes, neutral genes, group carbohydrate
and emm genes have previously been documented [20, 21,
46, 47, 48], and such transfers may create mosaic
chromosomal backgrounds and potentially alter the viru-
lence potential of the strains involved. Our data indicate
that lateral gene transfer is ongoing in our streptococcal
population, although such events did not seem to be
particularly associated with highly virulent strains. The
identification of multiple SAg genes and SlaA in non-
invasive GGS was suggestive of lateral gene transfers from
GAS to GGS: The detection of speC-H-I and SlaA in GGS
indicate phage-mediated genetic transfers, while we might
speculate that the chromosomally encoded speG and smeZ
have been transferred from GAS to GGS by conjugation.
speH, speI and SlaA have to our knowledge not previously
been documented in SDSE, but orthologues of these genes
have been identified in strains of Streptococcus equi subsp.
equi associated with clinical infection or carriage in horses
[49].
The virulence gene profiles were highly conserved
within most of the emm types in our material, indicating a
link between emm type and phage preference. Results
from previous studies have also suggested a correlation
between emm type and specific SAg gene profiles in GAS
[23, 50]. In line with these reports, we found that speAwas
highly prevalent among isolates bearing emm1 and emm3,
ssa was detected in the majority of isolates of emm3 or
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emm4, all our emm12 isolates harboured speH, and speC was
the most prevalent phage-encoded SAg. Although it is
noteworthy that ssa and speC were over-represented among
invasive isolates within certain emm types in our material, the
small number of isolates involved do not allow firm
conclusions to be drawn. The over-representation of speA
and SlaA among our invasive GAS isolates probably reflects
the genetic armament of isolates belonging to emm3. SlaA
seems to be a virulence factor, as an isogenic SlaA mutant
attenuated colonisation of epithelial cells and decreased tissue
destruction compared with the wild type parental strain in a
mouse model [51]. Recently, SlaA was found in the vast
majority of contemporary isolates belonging to emm3 and was
infrequently identified in isolates of other emm types,
including emm28 [52].
Among the GGS/GCS isolates in the present study,
speGdys correlated with certain emm subtypes, but was not
significantly linked to invasiveness. In two previous
studies from Japan, speGdys was identified in 19 out of
28 GCS/GGS isolates associated with STSS, and none of
these harboured SAgs previously identified in GAS [33,
53]. Furthermore, culture supernatants from GGS associ-
ated with STSS showed no mitogenic activity towards
peripheral blood mononuclear cells (PBNC), and recom-
binant proteins encoded by speGdys from the same
bacterial isolates stimulated PBCN only weakly in a recent
study [54]. These facts imply that speGdys and other SAgs
might not play a major role in the pathogenesis of severe
human disease caused by SDSE.
In conclusion, we found substantial emm gene diversity
and possible lateral transfers of phage-and chromosomally
encoded virulence genes in the natural population of GAS,
GCS and GGS. The over-representation of emm3 among
invasive GAS isolates in this small sample collected during
a limited time period, calls for continuous epidemiological
surveillance of the streptococcal population in our commu-
nity and further research into the pathogenesis associated
with this emm type.
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